Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 14.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 184,595 shares of the company's stock after acquiring an additional 23,440 shares during the period. Oberweis Asset Management Inc. owned 0.38% of Amphastar Pharmaceuticals worth $6,854,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. D.A. Davidson & CO. acquired a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $417,000. Barclays PLC lifted its holdings in shares of Amphastar Pharmaceuticals by 53.3% during the 3rd quarter. Barclays PLC now owns 74,456 shares of the company's stock worth $3,613,000 after acquiring an additional 25,878 shares during the period. Polaris Capital Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $910,000. Finally, Sanctuary Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 8.5% in the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company's stock worth $466,000 after acquiring an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analysts Set New Price Targets

AMPH has been the topic of a number of recent analyst reports. Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Trading Down 0.8 %

AMPH stock traded down $0.20 during midday trading on Wednesday, reaching $24.30. 190,915 shares of the company's stock traded hands, compared to its average volume of 464,025. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $53.96. The business has a 50-day moving average price of $26.77 and a two-hundred day moving average price of $36.19. The company has a market capitalization of $1.15 billion, a P/E ratio of 8.10, a PEG ratio of 2.19 and a beta of 0.79.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.